Literature DB >> 30850239

ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum.

Kazutoyo Miura1, Bingbing Deng2, Yimin Wu3, Luwen Zhou2, Thao P Pham2, Ababacar Diouf2, Chia-Kuei Wu3, Shwu-Maan Lee3, Jordan L Plieskatt3, Merribeth J Morin3, Carole A Long2.   

Abstract

The standard membrane-feeding assay (SMFA) is a functional assay that has been used to inform the development of transmission-blocking vaccines (TBV) against Plasmodium falciparum malaria. For Pfs230, a lead target antigen for TBV development, a few studies have tested either a single anti-Pfs230 polyclonal or monoclonal antibody (one antibody per study) at serial dilutions and showed a dose-dependent response. Further, there have been reports that the SMFA activity of anti-Pfs230 polyclonal and monoclonal antibodies were enhanced in the presence of complement. However, no analysis has been performed with multiple samples, and the impact of anti-Pfs230 antibody titers, IgG subclass profile and avidity were evaluated together in relation to transmission-reducing activity (TRA) by SMFA. In this report, a total of 39 unique anti-Pfs230 IgGs from five different mouse immunization studies were assessed for their ELISA units (EU), IgG2/IgG1 ratio and avidity by ELISA, and the functionality (% transmission-reducing activity, %TRA) by SMFA. The mice were immunized with Pfs230 alone, Pfs230 conjugated to CRM197, or a mixture of unconjugated Pfs230 and CRM197 proteins using Alhydrogel or Montanide ISA720 adjuvants. In all studies, the Pfs230 antigen was from the same source. There was a significant correlation between EU and %TRA (p < 0.0001 by a Spearman rank test) for the anti-Pfs230 IgGs. Notably, multiple linear regression analyses showed that both IgG2/IgG1 ratio and avidity significantly affected %TRA (p = 0.003 to p = 0.014, depending on the models) after adjusting for EU. The results suggest that in addition to antibody titers, IgG2/IgG1 ratio and avidity should each be evaluated to predict the biological activity of anti-Pfs230 antibodies for future vaccine development.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Avidity; IgG subclass; Pfs230; Plasmodium falciparum; Standard membrane-feeding assay; Transmission-blocking vaccine

Mesh:

Substances:

Year:  2019        PMID: 30850239      PMCID: PMC6718089          DOI: 10.1016/j.vaccine.2019.02.071

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

1.  Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines.

Authors:  Kazutoyo Miura; Andrew C Orcutt; Olga V Muratova; Louis H Miller; Allan Saul; Carole A Long
Journal:  Vaccine       Date:  2007-11-20       Impact factor: 3.641

2.  Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production.

Authors:  Saliha Eksi; Beata Czesny; Geert-Jan van Gemert; Robert W Sauerwein; Wijnand Eling; Kim C Williamson
Journal:  Mol Microbiol       Date:  2006-08       Impact factor: 3.501

3.  The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species.

Authors:  Lediya Cheru; Yimin Wu; Ababacar Diouf; Samuel E Moretz; Olga V Muratova; Guanhong Song; Michael P Fay; Louis H Miller; Carole A Long; Kazutoyo Miura
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

4.  N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity.

Authors:  Mayumi Tachibana; Yimin Wu; Hideyuki Iriko; Olga Muratova; Nicholas J MacDonald; Jetsumon Sattabongkot; Satoru Takeo; Hitoshi Otsuki; Motomi Torii; Takafumi Tsuboi
Journal:  Clin Vaccine Immunol       Date:  2011-06-29

5.  A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum.

Authors:  Christine E Farrance; Amy Rhee; R Mark Jones; Konstantin Musiychuk; Moneim Shamloul; Satish Sharma; Vadim Mett; Jessica A Chichester; Stephen J Streatfield; Will Roeffen; Marga van de Vegte-Bolmer; Robert W Sauerwein; Takafumi Tsuboi; Olga V Muratova; Yimin Wu; Vidadi Yusibov
Journal:  Clin Vaccine Immunol       Date:  2011-06-29

6.  Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity.

Authors:  P J Bustamante; D C Woodruff; J Oh; D B Keister; O Muratova; K C Williamson
Journal:  Parasite Immunol       Date:  2000-08       Impact factor: 2.280

7.  Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.

Authors:  Kazutoyo Miura; Eizo Takashima; Bingbing Deng; Gregory Tullo; Ababacar Diouf; Samuel E Moretz; Daria Nikolaeva; Mahamadou Diakite; Rick M Fairhurst; Michael P Fay; Carole A Long; Takafumi Tsuboi
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

8.  Three members of the 6-cys protein family of Plasmodium play a role in gamete fertility.

Authors:  Melissa R van Dijk; Ben C L van Schaijk; Shahid M Khan; Maaike W van Dooren; Jai Ramesar; Szymon Kaczanowski; Geert-Jan van Gemert; Hans Kroeze; Hendrik G Stunnenberg; Wijnand M Eling; Robert W Sauerwein; Andrew P Waters; Chris J Janse
Journal:  PLoS Pathog       Date:  2010-04-08       Impact factor: 6.823

9.  Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays.

Authors:  Kazutoyo Miura; Bingbing Deng; Gregory Tullo; Ababacar Diouf; Samuel E Moretz; Emily Locke; Merribeth Morin; Michael P Fay; Carole A Long
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

10.  Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.

Authors:  Kazutoyo Miura; David B Keister; Olga V Muratova; Jetsumon Sattabongkot; Carole A Long; Allan Saul
Journal:  Malar J       Date:  2007-08-08       Impact factor: 2.979

View more
  7 in total

1.  Lyophilized, antigen-bound liposomes with reduced MPLA and enhanced thermostability.

Authors:  Moustafa T Mabrouk; Wei-Chiao Huang; Bingbing Deng; Nasi Li-Purcell; Amal Seffouh; Joaquin Ortega; Gunes Ekin Atilla-Gokcumen; Carole A Long; Kazutoyo Miura; Jonathan F Lovell
Journal:  Int J Pharm       Date:  2020-09-02       Impact factor: 5.875

2.  Measuring antibody avidity to Plasmodium falciparum merozoite antigens using a multiplex immunoassay approach.

Authors:  Diane Wallace Taylor; Naveen Bobbili; Alex Kayatani; Samuel Tassi Yunga; Winifrida Kidima; Rose F G Leke
Journal:  Malar J       Date:  2020-05-01       Impact factor: 2.979

3.  Expression and purification optimization of an N-terminal Pfs230 transmission-blocking vaccine candidate.

Authors:  Shwu-Maan Lee; Jordan Plieskatt; Seetha Krishnan; Monika Raina; Rakeshkumar Harishchandra; C Richter King
Journal:  Protein Expr Purif       Date:  2019-04-10       Impact factor: 1.650

4.  Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230.

Authors:  Kazutoyo Miura; Eizo Takashima; Thao P Pham; Bingbing Deng; Luwen Zhou; Wei-Chiao Huang; Ababacar Diouf; Yonas T Gebremicale; Mayumi Tachibana; Tomoko Ishino; C Richter King; Jonathan F Lovell; Carole A Long; Takafumi Tsuboi
Journal:  NPJ Vaccines       Date:  2022-01-13       Impact factor: 7.344

Review 5.  Plasmodium 6-Cysteine Proteins: Functional Diversity, Transmission-Blocking Antibodies and Structural Scaffolds.

Authors:  Frankie M T Lyons; Mikha Gabriela; Wai-Hong Tham; Melanie H Dietrich
Journal:  Front Cell Infect Microbiol       Date:  2022-07-08       Impact factor: 6.073

6.  Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses.

Authors:  Brandon McLeod; Moustafa T Mabrouk; Kazutoyo Miura; Rashmi Ravichandran; Sally Kephart; Sophia Hailemariam; Thao P Pham; Anthony Semesi; Iga Kucharska; Prasun Kundu; Wei-Chiao Huang; Max Johnson; Alyssa Blackstone; Deleah Pettie; Michael Murphy; John C Kraft; Elizabeth M Leaf; Yang Jiao; Marga van de Vegte-Bolmer; Geert-Jan van Gemert; Jordache Ramjith; C Richter King; Randall S MacGill; Yimin Wu; Kelly K Lee; Matthijs M Jore; Neil P King; Jonathan F Lovell; Jean-Philippe Julien
Journal:  Immunity       Date:  2022-08-16       Impact factor: 43.474

7.  Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment.

Authors:  Wei-Chiao Huang; Bingbing Deng; Amal Seffouh; Joaquin Ortega; Carole A Long; Ragavan V Suresh; Xuedan He; Kazutoyo Miura; Shwu-Maan Lee; Yimin Wu; Jonathan F Lovell
Journal:  NPJ Vaccines       Date:  2020-03-18       Impact factor: 7.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.